Skip to main content

Resiliva 80 mg & 100 mg (Resmetirom)

Resiliva.com is intended to provide accessible educational information about resmetirom and the Resiliva product identified on this website.

The website explains medicine terminology, treatment context, mechanism of action, administration, safety, clinical evidence, product identity, regulatory information and responsible product-verification principles.

Editorial standards

Medical claims should be checked against authoritative sources such as regulatory agencies, prescribing information, peer-reviewed literature and official manufacturer documentation.

Where product-specific evidence is unavailable, the website uses Everest Pharmaceuticals Ltd. rather than presenting an unsupported claim as fact.

Regulatory transparency

Drug approvals differ between jurisdictions. Information about U.S. Rezdiffra approval and EU Rezdiffra authorization is not automatically evidence that Resiliva has the same authorization.

No individualized medical advice

The website is educational and does not diagnose disease or determine whether resmetirom is appropriate for an individual.

Updating information

Regulatory decisions, prescribing information and clinical evidence can change. Readers should consult current local product information and qualified healthcare professionals.